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Abstract 
Background 
Seventy percent of women in Scotland have at least one baby, making pregnancy an 
opportunity to help most young women quit smoking before their own health is irreparably 
compromised. By quitting during pregnancy their infants will be protected from miscarriage 
and still birth as well as low birth weight, asthma, attention deficit disorder and adult 
cardiovascular disease. In the UK, the NICE guidelines: ‘How to stop smoking in pregnancy 
and following childbirth’ (June 2010) highlighted that little evidence exists in the literature to 
confirm the efficacy of financial incentives to help pregnant smokers to quit. Its first research 
recommendation was to determine: Within a UK context, are incentives an acceptable, 
effective and cost-effective way to help pregnant women who smoke to quit? 
Design and methods 
This study is a phase II exploratory individually randomized controlled trial comparing 
standard care for pregnant smokers with standard care plus the additional offer of financial 
voucher incentives to engage with specialist cessation services and/or to quit smoking during 
pregnancy. 
Participants (n = 600) will be pregnant smokers identified at maternity booking who, when 
contacted by specialist cessation services, agree to having their details passed to the NHS 
Smokefree Pregnancy Study Helpline to discuss the trial. The NHS Smokefree Pregnancy 
Study Helpline will be responsible for telephone consent and follow-up in late pregnancy. 
The primary outcome will be self reported smoking in late pregnancy verified by cotinine 
measurement. An economic evaluation will refine cost data collection and assess potential 
cost-effectiveness while qualitative research interviews with clients and health professionals 
will assess the level of acceptance of this form of incentive payment. The research questions 
are: What is the likely therapeutic efficacy? Are incentives potentially cost-effective? Is 
individual randomization an efficient trial design without introducing outcome bias? Can 
incentives be introduced in a way that is feasible and acceptable? 
Discussion 
This phase II trial will establish a workable design to reduce the risks associated with a 
future definitive phase III multicenter randomized controlled trial and establish a framework 
to assess the costs and benefits of financial incentives to help pregnant smokers to quit. 
Trial registration 
Current Controlled Trials ISRCTN87508788 
Keywords 
Intervention, maternal and child health, outcomes, pregnancy, prevention, smoking 
Background 
Smoking during pregnancy increases miscarriage and stillbirth, accounting for up to 4000 UK 
deaths annually, and pre-term birth and low birth weight leading to perinatal morbidity [1]. A 
third of excess stillbirths and post-natal deaths associated with living in deprived areas are 
explained by smoking during pregnancy [2]. In Scotland 70% of women have a baby [3], 
making pregnancy an opportunity to help most women quit before their health is permanently 
compromised. In 2009, 24% of women booking for maternity care self-reported as current 
smokers [4]. Less than 1 in 20 of these women quit [5]. A study in the USA [6] in 2001 
calculated the additional first year costs to health services as $1200 per smoker. Smoking is a 
major preventable cause of premature mortality for the mother, and lifelong benefits of 
quitting for children include reduced incidence of asthma and attention deficit disorder. 
Following the 1998 White paper ‘Smoking Kills’, evidence-based National Health Service 
(NHS) smoking cessation services using behavioral support were developed [7-9] and now 
exist throughout Scotland [5]. Most of these services aim to provide tailored support (referred 
to in this paper as NHS Smokefree Pregnancy Services - NSPS) to pregnant women on a one-
to-one basis, and evidence suggests that such interventions during pregnancy are effective 
[10]. Nicotine replacement therapy (NRT) is also offered, although its efficacy in pregnancy 
is not yet clear [10]. In Greater Glasgow & Clyde (GG&C), with 15,000 pregnancies per 
year, pregnant smokers identified at maternity booking are currently routinely referred to the 
NSPS on an ‘opt-out’ basis, without consent for transfer of contact information [7]. This 
practice is in keeping with the recent National Institute for health and Clinical Excellence 
(NICE) guidelines in the UK [11]. Women are then contacted by NSPS advisers who ask if 
they would like to quit and offer a face-to-face appointment in a clinic or home setting. If the 
client attends they set a quit date and a risk assessment for use of NRT during pregnancy is 
performed. 
Participation figures for areas with recognized specialist smoking cessation in pregnancy 
services from a Scotland-wide audit are shown below [5]: 
A. Estimated number of pregnant smokers at maternity booking [12], 8170 (100%) 
B. Smokers identified by self report at routine booking questionnaire, 6128 (75%) 
C. Smokers referred to specialist pregnancy cessation services, 3188 (39%) 
D. Smokers engaged - face to face contact with specialist cessation service, 763 (10%)
a
 
E. Smokers who ‘set a quit date’, 779 (10%) 
F. Smokers who had quit 4 weeks later, 236 (3%) 
a
Different denominator 
In Scotland, all women who book for maternity care are asked if they are current, former or 
never smokers (B above). At present 25% deny their habit (A to B) [12]. This problem is 
being addressed by routinely testing all pregnant women at maternity booking for carbon 
monoxide using a breath test [11]. Only half were referred (B to C) due to busy clinics and 
perceived client disapproval. Only 10% reached specialist cessation services such as those 
available in Glasgow (D). Nearly all of these ‘set a quit date’ (E) and 3 in 10 (F) quit. Some 
improvement (E to F) may be possible as 4 in 10 quit [13] with support from NHS cessation 
services in other parts of the UK. 
Incentives are thought to increase participation and engagement [14,15], retention [16,17], 
and cessation [15-18]. If offered incentives, women who deny smoking may report as current 
smokers (A to B). Clients may self-refer or ask to be referred (B to C). With incentives, a 
greater proportion may engage (C to D) [5]. Improvement in the numbers quitting (D to F) 
will follow. In Scotland, when more pregnant smokers were referred, more engaged and more 
quit [5]. 
A 2009 Cochrane systematic review of interventions for promoting smoking cessation during 
pregnancy [10] asked: Do interventions improve quit rates? Are some interventions better 
than others? Figure 1 is a funnel plot describing the outcome from all included trials showing 
intervention better than control to the left. Fewer small trials on the right (control better than 
intervention) indicates some publication bias so the pooled risk ratio 0.94 may overestimate 
any combined positive effect. The four incentives trials showed significantly better outcomes 
than other interventions: pooled risk ratio 0.76 (95% confidence interval (CI) 0.71 to 0.91). 
Figure 1 Funnel plot. Figure 1 is a funnel plot of all studies included in the Cochrane 
systematic review: interventions for promoting smoking cessation during pregnancy [10]. 
The overall risk ratio for smoking cessation in each study is plotted on the x axis. The sample 
size of each study is plotted on the y axis. The plot illustrates possible publication bias with a 
gap caused by ‘missing’ studies upsetting the symmetry on the right hand side of the figure, 
indicating that small negative studies may not have reached the point of publication. 
Diamond shaped symbols indicate individual randomization whereas square symbols indicate 
that cluster randomization was used in the trial. The four black diamond shapes on the left 
side represent the four incentives trials included in the review. The dashed vertical line 
crosses the x axis at the weighted mean risk ratio of smoking reduction in all studies 
comparing intervention with control – 0.94 (95 % confidence interval 0.93 to 0.95) 
However, the incentives trials are all from the USA. The first trial was conducted 25 years 
ago and only included incentives as a minor part of an extensive intervention. Other 
incentives trials were small [16-18] and did not have a ‘no incentive’ control group [17,18]. 
None attempted to measure change in participation or engagement with an intervention. The 
NICE guidelines [11] issued in June 2010 highlighted that little evidence exists in the 
literature to confirm the efficacy of financial incentives to help pregnant smokers to quit. Its 
first research recommendation was: “Within a UK context, are incentives an acceptable, 
effective and cost-effective way to help pregnant women who smoke to quit?” 
Since 2007, NHS Tayside in Scotland has piloted an incentives model - £12.50 per week of 
supermarket vouchers - to reward smoking cessation from quit date to 3 months after birth. 
The total payment for quitters is up to £650. The project has no formal contemporaneous 
control group but the number of women accessing cessation support has increased since 
incentives were introduced [19]. Women access the service at their local pharmacies, which 
provide NRT as well as support and validate whether the client has stopped smoking. This 
information initiates a payment onto a store card. During 2009, 169 (14%) of about 1200 
pregnant smokers [5] joined the program (the equivalent of engagement) and 94 (8%) women 
had quit smoking 4 weeks later; 42 were still quit at delivery (personal communication, 
Andrew Radley). This cessation rate is higher than those obtained by other Scottish smoking 
cessation in pregnancy services, where the average quit rate at 4 weeks is 3%, and the best 
5% [5]. A feasibility study for an incentives trial in Glasgow reported in January 2009 [20]. It 
explored how the Tayside program could be adapted for service configuration in Glasgow. 
The feasibility study provided the foundation for development of this trial. 
This phase II trial will provide the tools required to run a future appropriately powered 
definitive phase III multicenter randomized controlled trial. The aim of that future phase III 
trial will be to establish whether or not incentives increase engagement with services, quit 
attempts and successful cessation to provide a more cost-effective pregnancy smoking 
cessation service model generalizable to the whole UK and beyond. 
Design and methodology 
Population 
In 2010 there were 58,051 births in Scotland with 14,155 (24%) to mothers resident in NHS 
GG&C Health Board area. Twenty-six percent of births in Scotland are to women who live in 
the most deprived quintile, whereas in GG&C it is 44% [21]. Of the most deprived women 
who were asked, 35% self reported that they smoked at maternity booking compared with 
7.1% of the least deprived [22]. Overall, in GG&C 25% of women self report as current 
smokers at maternity booking. 
Design 
The study is designed as a phase II single blinded (outcome assessor blind to randomization 
status at follow-up telephone contact) individually randomized controlled trial. The 
procedures are illustrated schematically in Figure 2 and detailed in the text. 
Figure 2 Flow diagram for Cessation in Pregnancy Incentives Trial (CPIT). Figure 2 
projects the flow of pregnant women through the trial over a 12-month period. In the NHS 
Greater Glasgow & Clyde study area, 15,000 pregnancies are recorded at maternity booking; 
5,000 are to smokers, some who conceal their habit, and 3,000 are identified at maternity 
booking by self-report as current smokers. Their information is routinely passed to NHS 
Smokefree Pregnancy Services (NSPS) using an automated system. Attempt is made to 
contact all self reported smokers. We estimate that 500 will not be contactable by NSPS and 
that 500 will decline permission for their details to be passed to the NHS Smokefree 
Pregnancy Study Helpline (Study Helpline). Once details have been passed, 500 will not be 
contactable leaving 1,500 contacted by the Study Helpline. We expect that 600 to 900 will 
decline consent leaving 600 to 900 who agree to enroll in the study over 12 months. Of these, 
300 will be randomly allocated to the intervention group to be offered incentive payments as 
well as standard care to stop smoking during pregnancy and 300 will be randomly allocated 
to receive the offer of standard care without incentive payments to quit smoking 
Research questions 
Research II trial 
1. 
What is the likely therapeutic efficacy of financial incentives to encourage women to 
attend specialist cessation services, to set a quit date, to quit smoking and be abstinent at 
34 to 38 weeks gestation towards the end of pregnancy? 
2. 
Is individual randomization an efficient trial design without compromising validity 
through bias due to differential follow-up of disaffected control arm participants? 
Health economic study 
3. 
Are incentives potentially a cost-effective means of helping pregnant women to stop 
smoking? 
Qualitative study 
4. 
Can incentives be introduced in a way that is feasible and acceptable to women and 
service providers and are there any unintended consequences? 
NHS Smokefree Pregnancy Services Greater Glasgow & Clyde Health Board 
area 
At their maternity booking appointment pregnant women in NHS GG&C are asked for 
consent for screening which includes procedures to identify and offer treatment to current 
smokers – self report and routine carbon monoxide breath test with follow-up by NSPS. All 
women with either a carbon monoxide level of 5 ppm and above or self reported as current 
smokers (at least 1 cigarette in the last week) are notified to NSPS using a rapid electronic 
system. NSPS advisers contact these women by telephone and offer a smoking cessation 
counseling service which utilizes ‘Withdrawal Oriented Therapy’ [23]. Support includes a 
face-to-face appointment, weekly telephone support for 4 weeks and the offer of NRT 
dispensed by local pharmacies free of charge to support a quit attempt for up to 12 weeks. 
Trial inclusion criteria 
Participants must satisfy the following criteria to be included in the study: 
• age at least 16 years and pregnant less than 24 weeks gestation at maternity booking 
• self report as current smokers 
• 
have a carbon monoxide breath test result of 7 ppm or greater - NICE guideline level for 
referral of pregnant smokers – PH26 [11] 
• live in the NHS GG&C Health Board area 
• 
give permission for their contact details to be passed to NHS Smokefree Pregnancy Study 
Helpline 
• 
be able to understand and speak English in order to provide verbal telephone consent to 
take part in the trial. 
Screening 
Early in the first telephone contact call from an NSPS adviser, eligible smokers will be given 
information about the trial and asked to give their verbal permission for contact details to be 
passed to the NHS Smokefree Pregnancy Study Helpline so that formal trial telephone 
consent procedures can take place. The Caldicott Guardian has approved this verbal 
permission required to pass this contact information. Those who give permission for contact 
details to be passed will be sent a letter and a trial information sheet outlining the nature and 
importance of the trial. The NSPS adviser will then continue with standard treatment and 
follow-up procedures. 
Recruitment 
We will enroll 600 eligible pregnant smokers to this phase II trial over a 12 month period. 
This is illustrated in Figure 2 based on existing throughput from local services in the study 
area and is a conservative time period taking into account smokers not identified or referred 
and those who decline consent to take part in the incentives trial. We expect high enrollment 
of eligible smokers and that knowledge of the trial will increase eligible smokers who agree 
to consider cessation during this pregnancy and consent to take part in the trial. 
Consent and randomization procedure 
At least 7 days after the first NSPS contact call, eligible smokers who allow their contact 
details to be passed on will be contacted by the Helpline to undergo formal consent 
procedures. Telephone contact will be attempted on three occasions at the time slot preferred 
by the client - weekday, evening or weekend - after which no further attempts at enrollment 
will be made. During the consent call potential participants will be fully informed about the 
nature and relevance of the trial, and exactly what will be involved if they agree to take part. 
Early in the consent call potential participants will be asked to provide information not asked 
for at maternity booking including questions measuring level of addiction to nicotine and 
partner smoking habits. Audio recordings of the consent process will be stored in accordance 
with Good Clinical Practice guidelines. Eligible smokers who consent to take part in the trial 
will be sent a written copy of their consent form. Individuals who give informed consent will 
be enrolled in the trial and randomized. The random allocation will be fed back to the 
participant. The Helpline adviser cannot influence or predict the random allocation which is 
integrated into the clinical information system. It will also provide a concealed (not available 
to the NHS Smokefree Pregnancy Study Helpline adviser during the consent call) random 
date between 34 and 38 weeks gestation for this pregnancy when the Helpline will contact the 
participant again to ascertain the primary outcome measure of self reported smoking during 
the last 8 weeks which will be corroborated by cotinine measurement. 
Baseline (pre-randomization) data collection 
Identification and contact 
Patient name, address, full postcode, telephone numbers (home, mobile, office) 
Best time to call, best number, estimated date of delivery, name of referrer, General 
Practitioner name 
Eligibility criteria 
Self reported smoking status at maternity booking, carbon monoxide breath test level at 
maternity booking, date of carbon monoxide reading, age at first telephone contact, English 
speaking, gestation at booking, consent, copy of consent form sent 
Smoking addiction level and other 
Fagerstrom questions [24] score out of 10, parity, partner smokes 
Randomization 
Randomization will be embedded within the trial database. The random allocation sequence 
will be generated by the Robertson Centre for Biostatistics, University of Glasgow (part of 
the Glasgow Clinical Trials Unit), using the method of randomized permuted blocks, with a 
block length of 4. In addition, a random date between 34 and 38 weeks gestation for each 
pregnancy will be generated as the date for primary outcome data collection. Patient details 
will be entered prior to randomization so that the allocation is concealed from Helpline staff 
and the client until after the patient has been enrolled in the study and provided baseline 
information. The participant will be informed of their random allocation group towards the 
end of the Helpline ‘trial consent’ telephone contact call, but will not be informed of the date 
when their primary outcome data will be collected. 
For a period during trial recruitment an extra consent question will be ‘turned on’ during the 
consent call asking clients also to consent to being contacted by trial staff for the purposes of 
one-to-one interviews to fulfill qualitative aspects of this research trial. 
Voucher incentive payments 
Those allocated to the intervention group will be offered financial incentives - Love2Shop 
vouchers - that can be redeemed in a wide array of UK shops but not used for the purchase of 
cigarettes or alcohol. The total amount available is £400 if women remain abstinent at each 
monitoring point. Women will receive incentive payments outlined below: 
£50 for attending a face-to-face appointment with their NSPS adviser and setting a quit date; 
£50 if quit 4 weeks after their quit date corroborated by a carbon monoxide breath test result 
less than 10 ppm collected by a research nurse; 
£100 if quit after 12 weeks corroborated by a carbon monoxide breath test collected by a 
research nurse; 
£200 if they self report quit for at least 2 months when contacted for primary outcome 
assessment by the Helpline at 34 to 38 weeks gestation. This will be corroborated by a carbon 
monoxide breath test result less than 10 ppm collected by a research nurse. 
Trial participation payments 
In order to minimize loss to follow-up, particularly among control participants, £25 will be 
given to all participants if they provide primary outcome information (and required samples 
to corroborate abstinence) at 34 and 38 weeks gestation. 
Quantitative data collection 
Primary outcome 
Smoking status at 34 to 38 weeks gestation, towards the end of pregnancy 
Follow-up telephone contact will be attempted by NHS Smokefree Pregnancy Study Helpline 
at a random date between 34 and 38 weeks gestation allocated at the time of the initial 
randomization. A patient record check will be made by the NHS Smokefree Pregnancy 
Service administrator looking for stillbirth, miscarriage or patient death the week prior to the 
telephone contact at 34 to 38 weeks gestation. Miscarriage or stillbirth may not preclude a 
woman from receiving vouchers if they are in the intervention group. 
Three attempts will be made to contact participants. If no contact is possible the participants 
will be followed up by the research nurse either by telephone or by a home visit after a 
contact detail check with the participant’s General Practitioner. If participants self report as 
non-smokers then a research nurse will make an appointment to collect urine and saliva for 
cotinine estimation (as well as a breath test for carbon monoxide to trigger the incentive 
payment.) 
If successful contact is made, the participant will be asked: ‘Have you smoked in the last 8 
weeks?’ If yes ‘Have you smoked more than 5 cigarettes in that time?’ Self report will be 
corroborated by cotinine estimation on saliva and urine. Urine (cut-off 44.7 ng/ml) or saliva 
(cut-off 14.2 ng/ml) cotinine will be measured by ABS laboratories limited 
(abslabs@biopark.org.uk). 
The important aspect of the primary outcome for this phase II trial is the proportion of 
participants successfully followed up from the intervention but particularly the control group. 
If acceptable levels (about 90%) of participants can be successfully followed up with a 
similar proportion in the intervention and control groups, then individual randomization can 
be accepted as a design choice for a future phase III trial that does not produce significant 
bias due to differential loss to follow-up between groups. 
Secondary outcomes 
Engagement with specialist pregnancy cessation services is achieved if the participant arrives 
at a first face-to-face appointment with the NSPS adviser and sets a quit date. 
Quit at 4 weeks after quit date will be ascertained with the question ‘Have you smoked in the 
last 2 weeks, even a puff?’ at routine telephone contact by the NSPS adviser. This will be 
corroborated by a carbon monoxide breath test collected at routine pharmacy visits to collect 
NRT. These data will be available from both intervention and control groups. 
Birth weight 
The best methods to gather these data efficiently will be examined and tested. Maternal 
height and weight is recorded routinely at maternity booking and will be used to help clarify 
birth weight differences during data analysis. Babies of smokers are on average 300 g (10%) 
lighter than babies born to non-smokers [25]. 
Unintended consequences 
We do not anticipate the provision of extra finance to participants will have any adverse 
effects. We are not systematically documenting adverse events that happen during pregnancy. 
We are, however, examining unintended consequences formally using in-depth interviews 
with a sample of enrolled clients. Such possible unintended consequences include, for 
instance, taking up smoking prior to maternity booking in order to receive incentive payments 
by stopping afterwards. 
Health economics 
Economic analysis will be undertaken alongside the trial, utilizing the costs, resource use and 
effectiveness data generated within the trial. For example, the cost of financial incentives, 
NRT, service delivery, and so on, will be collected and combined with resource use data. The 
number of quitters at the end of the trial will be combined with the cost data to calculate the 
incremental cost per late pregnancy quitter. The secondary outcome measure of child birth 
weight is strongly related to health care costs. Birth weight will be used to determine any 
difference in weight and therefore health care costs between neonates of mothers in the 
intervention group compared to mothers allocated to the control group. 
Health economic assessment 
A within-trial analysis will explore the incremental cost per late pregnancy quitter, followed 
by a longer term analysis incorporating the cost to the NHS of any difference in birth weight 
due to smoking and looking at potential lifetime quality-adjusted life year (QALY) gains to 
the mother and child. 
A health economic model we previously developed [26] (which uses a Markov design to 
model the lifetime likelihood and impact of cessation, expressing the long-term health 
benefits of quitting smoking in terms of QALYs saved and the potential long-term reduced 
costs to the health service of cessation) will be used. This model will be adapted to 
incorporate the trial information and relevant published evidence in order to capture the short 
and longer term costs and health gains for both mother and child of smoking cessation during 
pregnancy. The outcomes will be presented in terms of the incremental cost per QALY saved. 
The model will be analyzed probabilistically in order to characterize uncertainty in the 
parameters, and estimate confidence limits around the cost and effectiveness outcomes. Areas 
of uncertainty identified within the model will help inform decisions about the potential value 
of future research. This model will ascertain whether any (and what type of) data should be 
collected to inform a more definitive economic evaluation and contribute to the optimal 
design of a Phase III trial. 
Analysis 
Analysis of outcomes will be by intention-to-treat, as the intervention is the offer of financial 
incentives to engage with cessation services and to quit smoking. 
Differences by subgroup (maternity unit, deprivation score, age group, and so on) will be 
explored. 
Sample size 
The study is not designed to be able to detect a specified difference in the primary outcome of 
quit rate at 34 to 38 weeks gestation. The main objective is to inform the feasibility and 
design of a future definitive trial. However, assuming a quit rate of 4% in the usual care arm 
of the study, then with 600 participants the study will have 90% power to detect an increase 
in quit rates to 11.4%, or 80% power to detect an increase to 10.2%, based on a continuity-
corrected χ2 test at a 5% level of significance. Even if these outcome rates were achieved in 
this study, a Phase III study would be required to demonstrate that the intervention can be 
effective in other settings. 
Overview of qualitative research components 
Qualitative outcomes 
The qualitative research will take the form of a process evaluation designed to inform aspects 
of the proposed trial. It will contribute to: 
• 
assessing the feasibility and acceptability to women and service providers of using 
incentives to promote cessation during pregnancy (including identification of barriers and 
facilitators) 
• identifying any unintended consequences of participation 
• exploring responses to randomization approaches 
• 
providing guidance on how the intervention might be modified for the Phase III 
randomized controlled trial 
Interviews will be conducted with small samples of (i) pregnant women and (ii) relevant 
professionals by researchers at Stirling University led by Susan MacAskill. This work will 
expand on qualitative research already undertaken with clients and professionals in relation to 
‘Give it up for Baby’, the incentives scheme in Tayside [19]. 
Qualitative interviews will be conducted with pregnant women and professionals using semi-
structured topic guides developed in line with the research aims. Topics will not be explored 
in a prescriptive manner but as part of an open discussion. This flexible format will enable 
additional salient topics and insights to emerge. In broad terms, the focus for the different 
respondent groups will be as follows: 
One-to-one interviews with pregnant women (all of whom have engaged with the service) 
will explore views on issues around the delivery and promotion of the cessation service, 
response to incentive features and randomization, and any unintended consequences. Those 
interviewed prior to the trial start will be asked to respond to the concept of the incentives 
and the trial elements in addition to routine service elements, whilst those interviewed during 
the trial will also be asked to respond to these elements but based on personal experience of 
the trial. 
Focus group interviews with pregnant women (smokers/recent ex-smokers) interviewed 
before the trial starts will also explore views on issues around the delivery and promotion of 
the cessation service, response to incentive features and randomization, and any unintended 
consequences. Responses can incorporate personal experiences, but will largely be based on 
response to the concept of these issues. 
Interviews with professionals will explore issues around implementation of the intervention 
and the trial elements, identify challenges and ways they have been overcome, and perceived 
response among participants. 
With the participants’ consent, all interviews and focus group discussions will be recorded as 
digital audio files, which will then be transcribed in full for thematic analysis. Transcripts 
will be organized using a thematic framework based on topics specified in the topic guide and 
emerging themes identified through a process of familiarization with transcript texts. 
Sample and recruitment for the qualitative element 
Prior to the trial starting, up to 10 pregnant smokers will be recruited from amongst those 
already in contact with NSPS in Glasgow. Women will be informed about the study by 
specialist advisers on smoking in pregnancy and asked if they are interested in participating. 
Those interested will be provided with an information sheet and will be asked if their details 
can be passed to the lead qualitative researcher. Those who consent to their details being sent 
on will be contacted by phone to address any queries and to arrange an interview time and 
place. Alternatively, if they consent at the time of the initial information being provided, 
interviews can be conducted following their second session with the specialist advisor. 
Interviews will be conducted face to face and written consent obtained. 
In addition, two one-off focus groups (4 to 8 respondents each) with pregnant women 
(incorporating smokers/recent ex-smokers) will be conducted. Women will be recruited by 
the researcher through ante-natal classes or other appropriate groups attended by pregnant 
women and again explanations will be given and consent sought to participate. 
During the trial an additional 20 women will be interviewed after they have engaged with the 
trial. These will be different women from those interviewed prior to the trial. Pregnant 
smokers will be informed about this part of the study by the NHS Smokefree Pregnancy 
Study Helpline and asked if they are interested in participating in the interviews as part of the 
initial consent process. Details of those who express an interest and consent to be contacted 
will be passed to the research team. Points at which individuals will be interviewed will be 
spread across the pregnancy (that is, at around 4, 12 and 20 weeks post-set quit date). 
Mechanisms will be in place to ensure there are no contraindications prior to re-contacting 
those to be interviewed in later pregnancy (for example, any adverse pregnancy outcomes 
such as miscarriage). Both continued participants and those who have dropped-out will be 
included in the sample. 
Respondents will be recruited from two hub areas in Glasgow and Clyde. All pregnant 
women participants will be offered £20 in recognition of their contribution to the study. 
Professionals will also be interviewed as part of the qualitative study. They will be 
approached through appropriate organizational structures, facilitated by study co-applicants. 
Information sheets will be provided and consent obtained. The professional sample is 
intended to reflect a range of perspectives on implementation and the conduct of the trial. 
They will therefore include: pregnancy smoking cessation advisor(s) and manager, Clinical 
Research Facility nurse(s), interviews with the NHS Stop Smoking Study Helpline 
staff/managers, community midwives and manager, and community pharmacy facilitator(s). 
Professionals will be interviewed by telephone or face to face. 
Discussion 
In Scotland, up to a third of pregnant women smoke throughout pregnancy. This is 
responsible for a third of miscarriages, still births and sudden infant deaths during the first 
year of life. There would be significant long-term health gains for mother and child if 
smokers quit during pregnancy. At present, less than 10% of pregnant smokers take up the 
offer of free smoking cessation services and only 3% quit during pregnancy. Modest 
incentive payments to engage with cessation services and/or to quit smoking may provide a 
substantial benefit by decreasing pregnancy health care costs and first-year health care costs. 
If women stay smoke-free, long-term health care costs will be substantially reduced. The 
results of this phase II trial will reduce the risks associated with funding a definitive phase III 
multicenter trial. The phase III trial will examine the costs and benefits of providing financial 
incentive payments for smoking cessation during pregnancy. 
Ethics approval 
Ethics approval was received from West of Scotland REC2 on 25 May 2011. 
Caldicott guardian approval was given on 3 February 2011 to allow NSPS GG&C to pass 
information to the NHS Smokefree Pregnancy Study Helpline if the client gives verbal 
permission that contact details can be passed. 
A major amendment to the trial protocol was approved on 6 March 2012 to allow use of 
anonymized qualitative interview data by the Health Technology Assessment Programme 
10/31/02 BIBS: Benefits of Incentives for Breastfeeding and Smoking cessation: A platform 
study for a trial. 
Trial organization 
Trial Steering Committee 
The overall scientific aspects of the project will be managed by a Steering Committee. The 
Steering Committee will include the investigators above. The Steering Committee will take 
all executive decisions. 
The responsibility of the Steering Committee is to ensure the scientific integrity and quality 
of the project. To achieve this, the specific responsibilities of the Steering Committee 
include: maintaining adherence to the study protocol; approving changes to study protocol if 
required; reviewing quality assurance indicators; monitoring study recruitment and the 
overall study timetable; advising, as required, on specific scientific items that may arise; 
compliance with legislation; adherence to research governance; reporting to funders; 
approving publication and dissemination strategies. 
The Steering Committee will meet every 6 months. 
Project Management Group 
A Project Management Group (comprising as required principal investigators, a trial 
manager, a trial administrator, a senior manager from NSPS, a data manager from NHS 
Research and Development, a statistician, a senior representative from NHS Stop Smoking 
Study Helpline, a senior manager from NHS GG&C Research and Development, a health 
economist, a senior qualitative researcher) will run the trial on a day-to-day basis to ensure 
the smooth operation of the project. Review meetings will be held with other members of the 
team as appropriate. 
The responsibilities of the Project Management Group include: establishing and monitoring 
recruitment of participants; distributing and supplying data collection forms and other 
appropriate documentation for the trial; data collection and management; data entry and 
cleaning; data analysis; organizing and servicing the Trial Steering Committee. 
Data Monitoring Committee 
An independent Data Monitoring Committee will not be established as adverse events related 
to the financial incentives intervention are not envisaged and are not being systematically 
collected. 
Data Co-ordinating Centre 
The Data Co-ordinating Centre will be based at the Paediatric Epidemiology and Community 
Health Unit, Glasgow University. The responsibilities of the Data Co-ordinating Centre are to 
set up and run systems for data entry, data verification and the checking of errors and overdue 
data reports. 
Callcredit plc 
Callcredit plc, Leeds UK, will design and build the web based portal for data entry 
comprising the main Electronic Data Capture system. This system will allow NHS and 
research staff to enter data in a timely fashion triggering voucher incentive payments 
dispatched by Callcredit. 
NHS Stop Smoking Study Helpline 
NHS Stop Smoking Study Helpline will provide call centre services: the consent call for 
participant enrollment, and the final call to determine the primary outcome (self reported 
smoking at 34 to 38 weeks gestation). 
NHS Research and Development Glasgow & Clyde 
NHS Research and Development are supporting this trial by providing extra research nursing 
support for participant enrollment and follow-up and project assistance for data entry. 
The Robertson Centre for Biostatistics, University of Glasgow 
The Robertson Centre is part of the Glasgow Clinical Trials Unit, and will provide statistical 
analysis and reporting for the study. 
NHS Smoking in Pregnancy Services 
NSPS GG&C are discussing the trial with participants and asking permission for contact data 
to be passed outwith the NHS to The Listening Company Glasgow Scotland (a call centre 
with extensive experience working with the NHS and who are known for the trial as the NHS 
Stop Smoking Study Helpline) for the consent call. NSPS staff are providing an encrypted list 
of potential participants to the NHS Stop Smoking Study Helpline on a weekly basis. They 
are providing cost data for the economic analysis. 
Publication policy 
The primary results of the trial will be published with authorship in relation to specific 
participation in the study, with the name order to be presented by the principal investigators 
for consideration by the Trial Steering Committee. Suggested revisions in order of authors 
should meet with the approval of the principal investigators. Publications in specific areas of 
the study or on methodological aspects can be led by co-investigators in their area of 
expertise subject to approval by the Trial Steering Committee and the principal investigators. 
The requirements for authorship will follow recommended practice in journal guidelines. 
Confidentiality 
Encryption defined by NHS GG&C security management will be in place to pass data for 
potential participants from NSPS to NHS Smokefree Pregnancy Study Helpline, a process 
agreed by the Caldicott Guardian. Both NHS Smokefree Pregnancy Study Helpline and 
CallCredit plc have long histories of managing Government-related services and are able to 
demonstrate their commitment to data security and quality management through their 
ISO27001 and ISO9001 accreditations. Their ISO27001 accredited Information Security 
Management Systems demand that all of their systems and processes are maintained with 
confidentiality, integrity and availability of data at the core. In addition both companies are 
ISO9001 accredited, the internationally recognized standard for Quality Management 
Systems. During and after data analysis participants will be identified by their trial number to 
ensure confidentiality. 
Trial status 
Recruitment started in December 2011 and will be complete by the end of December 2012. 
On 6 March 2012, 78 of 600 were enrolled in the trial. 
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15,000 pregnancies during 12 months in study area4 
600 smokers consent for incentives9 trial during 12 months 
5,000 smokers5, 12
3,000 self reported smokers  
500 not contactable 
by  telephone5,7
600-900 decline consent9
SECONDARY OUTCOMES 
Proportion who set a quit 
300 control smokers  
Standard care 
No incentive offered 
Estimated from 
Tayside service  
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10,000 non-smokers
             300 intervention smokers 
Standard care + 
Incentive offered 
Proportion who have quit 4 weeks 
l
NSPS telephone all smokers and offer support to quit. Trial information will be given and verbal 
permission sought for contact detail transfer to NHS Smokefree Pregnancy Study Helpline
Estimated from 
Glasgow data  
174 (58%)5,7
 54 (18%)5,7103(34%
2000 smokers’ details passed to NHS Smokefree Pregnancy Study Helpline
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Identify and refer smokers All women asked (current, former, never smoker) 
at maternity booking. All results sent to the NHS Smokefree Pregnancy Service (NSPS)
PRIMARY OUTCOME 
Proportion quit at late pregnancy
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                     Birth weight  
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